Price T Rowe Associates Inc. MD Has $153,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Price T Rowe Associates Inc. MD cut its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 17.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,112 shares of the company’s stock after selling 5,346 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Olema Pharmaceuticals were worth $153,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $30,000. Hsbc Holdings PLC acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $58,000. Teacher Retirement System of Texas acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $60,000. Vontobel Holding Ltd. acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $62,000. Finally, Fox Run Management L.L.C. acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $80,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $4.71 on Friday. The firm has a 50-day simple moving average of $4.29 and a 200 day simple moving average of $6.08. Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $16.62. The stock has a market cap of $321.98 million, a PE ratio of -2.15 and a beta of 2.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 13th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. JPMorgan Chase & Co. lowered their target price on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, March 28th. Oppenheimer lowered their target price on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a report on Monday, April 28th. Finally, The Goldman Sachs Group decreased their price target on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.